{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:05:34Z","timestamp":1779858334661,"version":"3.53.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024A03J0304"],"award-info":[{"award-number":["2024A03J0304"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["20221A011050"],"award-info":[{"award-number":["20221A011050"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xphs.2025.103893","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:56:39Z","timestamp":1751388999000},"page":"103893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Defining the therapeutic reference range and optimizing a high-dose discontinuation strategy for Paroxetine based on TDM and population pharmacokinetics"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4061-2944","authenticated-orcid":false,"given":"Wanting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4505-798X","authenticated-orcid":false,"given":"Zhihao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.xphs.2025.103893_bib0001","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cpdd.948","article-title":"Impact of paroxetine, a strong CYP2D6 inhibitor, on SPN-812 (viloxazine extended-release) pharmacokinetics in healthy adults","volume":"10","author":"Wang","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"10.1016\/j.xphs.2025.103893_bib0002","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2174\/1570159X16666180813155017","article-title":"Psychopharmacological treatment of obsessive-compulsive disorder (OCD)","volume":"17","author":"Del Casale","year":"2019","journal-title":"Curr Neuropharmacol"},{"issue":"8","key":"10.1016\/j.xphs.2025.103893_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106337","article-title":"The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton rating scales","volume":"9","author":"Sugarman","year":"2014","journal-title":"PLOS One"},{"issue":"12","key":"10.1016\/j.xphs.2025.103893_bib0004","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1124\/dmd.114.059576","article-title":"Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5 % timolol eye drops","volume":"42","author":"M\u00e4enp\u00e4\u00e4","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2025.103893_bib0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.64719\/pb.4345","article-title":"Paroxetine\u2014The antidepressant from hell? Probably not, but caution required","volume":"46","author":"Nevels","year":"2016","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"10.1016\/j.xphs.2025.103893_bib0006","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/ph17030280","article-title":"Pharmacokinetics and pharmacodynamics: a comprehensive analysis of the absorption, distribution, metabolism, and excretion of psychiatric drugs","volume":"17","author":"Zakaraya","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.103893_bib0007","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.xphs.2025.103893_bib0008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review","volume":"84","author":"Fava","year":"2015","journal-title":"Psychother Psychosom"},{"issue":"7","key":"10.1016\/j.xphs.2025.103893_bib0009","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S2215-0366(24)00133-0","article-title":"Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis","volume":"11","author":"Henssler","year":"2024","journal-title":"Lancet, Psychiatry"},{"issue":"5","key":"10.1016\/j.xphs.2025.103893_bib0010","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41380-024-02782-4","article-title":"Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review","volume":"30","author":"Zhang","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"12","key":"10.1016\/j.xphs.2025.103893_bib0011","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","article-title":"Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database","volume":"45","author":"Gastaldon","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.xphs.2025.103893_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/10600280241231116","article-title":"Safety profile of selective serotonin reuptake inhibitors in real-world settings: a pharmacovigilance study based on FDA adverse event reporting system","author":"Zhao","year":"2024","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.xphs.2025.103893_bib0013","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1177\/0269881119845799","article-title":"Antidepressants, withdrawal, and addiction; where are we now?","volume":"33","author":"Jauhar","year":"2019","journal-title":"J Psychopharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.103893_bib0014","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000530692","article-title":"Discontinuation of antidepressant medications: a significant healthcare problem insufficiently addressed by the NICE guidelines","volume":"92","author":"Cosci","year":"2023","journal-title":"Psychother Psychosom"},{"issue":"6","key":"10.1016\/j.xphs.2025.103893_bib0015","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","article-title":"Tapering of SSRI treatment to mitigate withdrawal symptoms","volume":"6","author":"Horowitz","year":"2019","journal-title":"Lancet, Psychiatry"},{"issue":"5","key":"10.1016\/j.xphs.2025.103893_bib0016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/17151635231188340","article-title":"Antidepressant discontinuation and the role of the pharmacist","volume":"156","author":"Geen","year":"2023","journal-title":"Can Pharm J: CPJ"},{"issue":"20","key":"10.1016\/j.xphs.2025.103893_bib0017","first-page":"355","article-title":"Antidepressant withdrawal and rebound phenomena","volume":"116","author":"Henssler","year":"2019","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"10.1016\/j.xphs.2025.103893_bib0018","article-title":"Pharmacokinetics of immediate and sustained-release formulations of paroxetine: population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xphs.2025.103893_bib0019","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.2147\/DDDT.S84718","article-title":"Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics","volume":"9","author":"Kim","year":"2015","journal-title":"Drug Devel Ther"},{"issue":"5","key":"10.1016\/j.xphs.2025.103893_bib0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2125.2006.02629.x","article-title":"Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling","volume":"61","author":"Feng","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2025.103893_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105165","article-title":"Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in chinese han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis","volume":"104","author":"Liao","year":"2024","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.xphs.2025.103893_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","article-title":"How important are gender differences in pharmacokinetics?","volume":"41","author":"Meibohm","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.xphs.2025.103893_bib0023","doi-asserted-by":"crossref","first-page":"176","DOI":"10.12677\/acm.2024.14112862","article-title":"A study on the factors influencing the blood concentration and reference range of paroxetine in the treatment of patients with depression","volume":"14","author":"He","year":"2024","journal-title":"Adv Clin Med"},{"issue":"8","key":"10.1016\/j.xphs.2025.103893_bib0024","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1176\/ajp.155.8.1110","article-title":"Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline","volume":"155","author":"Pollock","year":"1998","journal-title":"Am J Psychiat"},{"issue":"6","key":"10.1016\/j.xphs.2025.103893_bib0025","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.npp.1300960","article-title":"Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder","volume":"31","author":"Findling","year":"2006","journal-title":"Neuropsychopharmacol"},{"issue":"Suppl 20","key":"10.1016\/j.xphs.2025.103893_bib0026","first-page":"21","article-title":"Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years","volume":"60","author":"Walters","year":"1999","journal-title":"J Clin Psychiat"},{"issue":"3","key":"10.1016\/j.xphs.2025.103893_bib0027","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4088\/JCP.v63n0302","article-title":"Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects","volume":"63","author":"Kennedy","year":"2002","journal-title":"J Clin Psychiat"},{"issue":"6","key":"10.1016\/j.xphs.2025.103893_bib0028","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.jcp.0000095342.32154.54","article-title":"A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.103893_bib0029","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-2004-818990","article-title":"Paroxetine in major depression: correlating plasma concentrations and clinical response","volume":"37","author":"Normann","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.xphs.2025.103893_bib0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13651500902903016","article-title":"Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms","volume":"13","author":"Van Nieuwerburgh","year":"2009","journal-title":"Int J Psychiat Clin"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.103893_bib0031","first-page":"e1","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"10.1016\/j.xphs.2025.103893_bib0032","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1176\/appi.ajp.159.10.1702","article-title":"Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine","volume":"159","author":"Gilmor","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.xphs.2025.103893_bib0033","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13651500902903016","article-title":"Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms","volume":"13","author":"Van Nieuwerburgh","year":"2009","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"651","key":"10.1016\/j.xphs.2025.103893_bib0034","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.3399\/bjgp16X686641","article-title":"Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care","volume":"66","author":"Bosman","year":"2016","journal-title":"Br J Gen Pr"},{"issue":"4","key":"10.1016\/j.xphs.2025.103893_bib0035","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen17X101265","article-title":"Withdrawal of unnecessary antidepressant medication: a randomised controlled trial in primary care","volume":"1","author":"Eveleigh","year":"2018","journal-title":"BJGP Open"},{"key":"10.1016\/j.xphs.2025.103893_bib0036","doi-asserted-by":"crossref","first-page":"l2238","DOI":"10.1136\/bmj.l2238","article-title":"Clinical guidelines on antidepressant withdrawal urgently need updating","volume":"365","author":"Davies","year":"2019","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.xphs.2025.103893_bib0037","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000506868","article-title":"Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications","volume":"89","author":"Cosci","year":"2020","journal-title":"Psychother Psychosom"},{"issue":"7","key":"10.1016\/j.xphs.2025.103893_bib0038","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/02698811221093032","article-title":"Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice","volume":"36","author":"Collins","year":"2022","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.xphs.2025.103893_bib0039","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320932452","article-title":"How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication","volume":"10","author":"Groot","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.xphs.2025.103893_bib0040","article-title":"Do withdrawal symptoms predict depression relapse after antidepressant cessation?","author":"Volkmann","year":"2025","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.xphs.2025.103893_bib0041","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JCP.0b013e3181c8ae80","article-title":"Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome","volume":"30","author":"Murata","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.xphs.2025.103893_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2022.10.005","article-title":"Antidepressant discontinuation syndrome: a state-of-the-art clinical review","volume":"66","author":"Fornaro","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2025.103893_bib0043","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.xphs.2025.103893_bib0044","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1111\/bcp.13741","article-title":"The impact of CYP2D6 mediated drug\u2013drug interaction: a systematic review on a combination of metoprolol and paroxetine\/fluoxetine","volume":"84","author":"MuhA","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2025.103893_bib0045","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/FTD.0000000000001096","article-title":"Impact of CYP2D6 genotype on paroxetine serum concentration","volume":"45","author":"Hole","year":"2023","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925003454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925003454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:48:25Z","timestamp":1779857305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925003454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0022354925003454"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103893","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining the therapeutic reference range and optimizing a high-dose discontinuation strategy for Paroxetine based on TDM and population pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103893"}}